CNW -- Athersys, Inc. and Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI - News; TSX: ANP - News) announced that Athersys has completed patient enrollment for its phase I clinical trial of MultiStem(R), its allogeneic stem cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. Top line results of the trial are expected to be announced midyear, upon completion of the four-month patient follow-up visits and analysis of results.
